Hydroxyzine hydrochloride
Hydroxyzinum PPH is a medicine with antihistamine, sedative, and anxiolytic effects.
Hydroxyzinum PPH is indicated for:
Before starting treatment with Hydroxyzinum PPH, the patient should discuss it with their doctor:
Treatment with Hydroxyzinum PPH may be associated with an increased risk of heart rhythm disorders, which can be life-threatening. Therefore, the patient should tell their doctor about any heart problems and about taking any other medicines, including those available without a prescription.
If the patient experiences heart symptoms such as rapid heartbeat (palpitations), breathing problems, loss of consciousness, they should immediately consult
their doctor. The patient should also stop taking Hydroxyzinum PPH.
Treatment should be discontinued at least 5 days before performing allergy tests or methacholine bronchial provocation tests to avoid affecting the results of these tests.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. Hydroxyzinum PPH may affect the action of other medicines. Other medicines may affect the action of Hydroxyzinum PPH.
This applies to the following medicines:
The patient should not take Hydroxyzinum PPH if they are taking medicines used to treat:
The patient should avoid concomitant use of Hydroxyzinum PPH and alcohol.
Hydroxyzinum PPH should not be used during pregnancy or breastfeeding.
Breastfeeding should be discontinued if it is necessary to use Hydroxyzinum PPH.
Women of childbearing age must use an appropriate method of contraception to prevent pregnancy during treatment with hydroxyzine.
In newborns whose mothers used hydroxyzine during late pregnancy and/or during delivery, the following symptoms have been observed immediately or a few hours after birth: tremors, stiffness, and/or muscle weakness, breathing problems, and urinary retention
(urinary retention).
Therefore, hydroxyzine is contraindicated during pregnancy.
Animal studies have not shown a negative effect on fertility. Data on the effect on human fertility are not available.
During treatment with Hydroxyzinum PPH, the patient should not drive vehicles, operate machinery, or use tools, as the medicine may impair reaction and concentration abilities.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor or pharmacist.
should be as short as possible.
For children under 6 years of age and older children who cannot swallow tablets, the availability of hydroxyzine in the form of a syrup should be checked – a form suitable for this age group.
In adults and children with a body weight over 40 kg, the maximum daily dose is 100 mg. The following doses of Hydroxyzinum PPH are usually used.
In the symptomatic treatment of anxiety
50 mg per day in 2-3 divided doses.
In severe cases, oral doses of up to 100 mg per day can be used.
In the symptomatic treatment of itching
Treatment should be started with a dose of 25 mg before bedtime, and therapy should be continued, increasing the dose if necessary, administering 25 mg 3 to 4 times a day.
In premedication before surgical procedures
50 mg in two doses or 100 mg in a single dose orally.
Dose adjustment
The dose should be adjusted individually, within the recommended dose range, depending on the patient's response to treatment.
The use of hydroxyzine in elderly patients is not recommended. If treatment is decided, it is recommended to start with half the recommended dose.
In elderly patients, the maximum daily dose is 50 mg.
In patients with liver failure, it is recommended to reduce the daily dose by 33%.
In patients with moderate or severe renal failure, due to reduced excretion of the medicine's metabolite, cetirizine, the used doses should be reduced.
In children with a body weight up to 40 kg, the maximum daily dose is 2 mg/kg body weight per day.
In children with a body weight over 40 kg, the maximum daily dose is 100 mg.
In the symptomatic treatment of itching
In premedication before surgical procedures
0.6 mg/kg body weight orally in a single dose.
The cumulative daily dose should not exceed 2 mg/kg body weight per day.
If the patient has taken or used a dose of Hydroxyzinum PPH that is too high, they should immediately contact the emergency services, especially if it concerns a child. In case of overdose, symptomatic treatment can be used. The patient's ECG should be monitored due to the possibility of heart rhythm disorders [including bradycardia (very slow heart rate)], such as QT interval prolongation or torsade de pointes.
Symptoms of Hydroxyzinum PPH overdose are: nausea, vomiting, tachycardia (accelerated heart rate), fever, drowsiness, disturbances of pupillary reflex, tremors, confusion or hallucinations, and then decreased consciousness, respiratory depression, seizures, hypotension, or heart rhythm disorders, as well as deepening coma and cardiopulmonary collapse.
There is no specific antidote.
The patient should not take a double dose to make up for a missed dose.
In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Hydroxyzinum PPH can cause side effects, although not everybody gets them.
Side effects may occur with the following frequency:
Very common (may affect more than 1 in 10 people):drowsiness.
Common (may affect up to 1 in 10 people):dry mouth, fatigue, headache, sedation (calmness).
Uncommon (may affect up to 1 in 100 people):nausea, malaise, fever, dizziness, insomnia, tremors, agitation, confusion.
Rare (may affect up to 1 in 1,000 people):tachycardia (accelerated heart rate), accommodation disorders, blurred vision, constipation, vomiting, hypersensitivity reactions, abnormal liver function test results, seizures, dyskinesia (involuntary, uncoordinated movements of limbs and other body parts), disorientation, hallucinations, urinary retention, itching, rash, urticaria, skin inflammation, hypotension.
Very rare (may affect up to 1 in 10,000 people):anaphylactic shock (caused by a severe, systemic allergic reaction, its symptoms are: shortness of breath, swelling of the throat and larynx, skin itching and redness, headache, feeling of "pressure", dizziness, significant weakness, up to loss of consciousness; in severe cases, it can be life-threatening), bronchospasm, angioedema (skin rashes in the form of irregular spots, blisters, and swelling), increased sweating, fixed drug eruption, acute generalized exanthematous pustulosis (pustular rash on reddened skin, which may be accompanied by swelling and general symptoms, e.g., fever), erythema multiforme (skin rash that can cause the formation of blisters and looks like small targets – a dark spot surrounded by a lighter area and a dark ring around), Stevens-Johnson syndrome (widespread rash with blisters and peeling skin, occurring mainly in the mouth, eyes, nose, and genital areas).
QT interval prolongation in the electrocardiogram, heart rhythm disorders of the torsade de pointestype , liver inflammation, loss of consciousness (fainting), blistering changes [e.g., toxic epidermal necrolysis (widespread rash with blisters and peeling skin, occurring mainly in the mouth, eyes, nose, and genital areas), pemphigoid (an autoimmune skin disease characterized by well-tensioned blisters, located in the area of reddened and swollen skin and apparently unchanged skin)], weight gain.
The patient should stop taking the medicine and immediately consult their doctor if they experience heart rhythm disorders, such as rapid heartbeat (palpitations), breathing problems, or loss of consciousness.
Additionally, the following side effects have been observed with cetirizine, the main metabolite of hydroxyzine, which may also occur after administration of hydroxyzine: decreased platelet count, aggression, depression, tics, involuntary movements, paresthesia, episodes of forced gaze with eye rotation, diarrhea, difficulty urinating, involuntary urination, asthenia (fatigue, weakness), edema, weight gain.
In some patients, during treatment with Hydroxyzinum PPH, other side effects may occur. If any of the side effects worsen or if any side effects not listed in the leaflet occur, the patient should tell their doctor or pharmacist.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects can help gather more information on the safety of the medicine.
There are no special recommendations for the storage temperature of the medicine.
Store in the original packaging to protect from moisture.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after: "EXP". The expiry date refers to the last day of the given month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Hydroxyzinum PPH, 10 mg, coated tablets are white or almost white, round, approximately 5.6 mm in diameter, biconvex, coated tablets, smooth on both sides.
Hydroxyzinum PPH, 25 mg, coated tablets are white or almost white, round, approximately 8.1 mm in diameter, biconvex, coated tablets with a dividing line on one side and smooth on the other side.
The dividing line on the tablet is only to facilitate breaking it, for easier swallowing, and not for dividing into equal doses.
The coated tablets are available in PVDC/PVC/Aluminum blisters containing 30 tablets, placed in a cardboard box.
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
tel. +48 22 364 61 01
Synoptis Industrial Sp. z o.o.
ul. Rabowicka 15
62-020 Swarzędz
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.